Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc (NYSE:ELAN), filed a Form 4 on September 22, 2026, reporting the acquisition of deferred stock units dated September 18, 2026.

Key Highlights

  • Reporting person: Jeffrey N. Simmons, identified as President, CEO, and Director of Elanco Animal Health Inc.
  • Transaction: Acquisition (code A) of 126.0897 deferred stock units on September 18, 2026.
  • Price per unit: $22.42, as stated in the filing.
  • Resulting holdings: Simmons beneficially owned 25,371.5983 deferred stock units following the transaction, held directly.
  • Unit definition: Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
  • Settlement terms: Units settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan.

Simmons Adds Deferred Stock Units Under Executive Deferral Plan

According to the filing, the transaction involves derivative securities recorded in Table II. On September 18, 2026, Simmons acquired 126.0897 deferred stock units with a stated price of $22.42 per unit. The filing notes that each deferred stock unit represents the right to receive one share of Elanco Animal Health Inc common stock or the cash equivalent, and that the units are held directly.

The filing discloses that these deferred stock units settle in cash or shares of Company common stock "following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan." No expiration date or specific exercise date was listed, consistent with the plan's deferred settlement structure. Following this reported transaction, Simmons's total beneficial ownership of deferred stock units stands at 25,371.5983, held on a direct basis.

The Form 4 was signed by Amy C. Seidel as Attorney-in-Fact for Jeffrey N. Simmons and filed with the SEC on September 22, 2026. No transactions in non-derivative securities (Table I) were reported in this filing.

What Was Disclosed

This Form 4 reports that Elanco Animal Health's President and CEO acquired 126.0897 deferred stock units at $22.42 on September 18, 2026, bringing his total direct beneficial ownership of such units to 25,371.5983, under the company's Executive Deferral and Stock Match Plan.